Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 12—December 2015
Dispatch

Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea

Wan Beom Park1, Ranawaka A.P.M. Perera1, Pyoeng Gyun Choe, Eric H.Y. Lau, Seong Jin Choi, June Young Chun, Hong Sang Oh, Kyoung-Ho Song, Ji Hwan Bang, Eu Suk Kim, Hong Bin Kim, Sang Won Park, Nam Joong Kim, Leo Lit Man Poon, Ghazi KayaliComments to Author , and Myoung-don OhComments to Author 
Author affiliations: Seoul National University College of Medicine, Seoul, South Korea (W.B. Park, P.G. Choe, S.J. Choi, J.Y. Chun, H.S. Oh, K.-H. Song, J.H. Bang, E.S. Kim, H.B. Kim, S.W. Park, N.J. Kim, M.-d. Oh); The University of Hong Kong, Pokfulam, Hong Kong, China (R.A.P.M. Perera, E.H.Y. Lau, L.L.M. Poon); Hong Kong University–Pasteur Research Pole, Pokfulam (M. Peiris)

Main Article

Table 2

Testing potential difference in rates of change in antibody titers over day of illness during the exponential phase of the antibody response, accounting for sequential measurements taken at different days of illness and adjusted for severity*

Clinical factors Difference in rates of change in log antibody titers
PRNT50 titer p value S1-ELISA OD ratio p value
Severe disease 0.09 0.01 0.08 0.07
Male sex† 0.07 0.05 0.14 0.01
Age >60 y† 0.05 0.22 −0.03 0.65
Incubation period, d† 0.01 0.16 0.02 0.004
Use of corticosteroid† 0.06 0.37 −0.04 0.58
Use of antiviral drugs† 0.06 0.10 0.05 0.35
Concomitant conditions† 0.06 0.06 0.07 0.16

*Differences in rates of change and p values were estimated by using linear mixed models; positive value indicates a faster increase in antibody titer. Given that the antibody titers exhibited an S-shaped pattern, the analysis was restricted to data for log-phase antibody responses by manually removing data from the inductive/steady-state phase. Increases in antibody titers during the log phase were compared by different factors, adjusted for disease severity, by using a linear mixed model to account for repeated measurements, assuming a linear increasing trend by days since illness onset. PRNT50 titers were first log-transformed (with base 10). OD, optical density; PRNT50, 50% endpoint plaque reduction neutralization test.
†Effects were adjusted for severity.

Main Article

1These authors contributed equally to this article.

Page created: November 17, 2015
Page updated: November 17, 2015
Page reviewed: November 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external